A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments

Simple Summary Here, we describe the main interactions of multiple myeloma cells in the bone marrow with non-hematological and hematological immune cells that impact the disease's progression and treatment resistance. Non-hematological cells in the bone marrow can secrete molecules that accelerate disease progression. On the other side, these interactions compromise immune cell activity, leading to immune evasion and disease progression. Deep knowledge of these interactions can lead to the design of improved treatments for multiple myeloma. Tumors are composed of a plethora of extracellular matrix, tumor and non-tumor cells that form a tumor microenvironment (TME) that nurtures the tumor cells and creates a favorable environment where tumor cells grow and proliferate. In multiple myeloma (MM), the TME is the bone marrow (BM). Non-tumor cells can belong either to the non-hematological compartment that secretes soluble mediators to create a favorable environment for MM cells to grow, or to the immune cell compartment that perform an anti-MM activity in healthy conditions. Indeed, marrow-infiltrating lymphocytes (MILs) are associated with a good prognosis in MM patients and have served as the basis for developing different immunotherapy strategies. However, MM cells and other cells in the BM can polarize their phenotype and activity, creating an immunosuppressive environment where immune cells do not perform their cytotoxic activity properly, promoting tumor progression. Understanding cell-cell interactions in the BM and their impact on MM proliferation and the performance of tumor surveillance will help in designing efficient anti-MM therapies. Here, we take a journey through the BM, describing the interactions of MM cells with cells of the non-hematological and hematological compartment to highlight their impact on MM progression and the development of novel MM treatments.

Automated summary

In this article, we discuss the interactions between multiple myeloma cells and non-hematological and hematological immune cells in the bone marrow, highlighting their effects on disease progression and treatment resistance. Non-hematological cells in the bone marrow can secrete molecules that accelerate disease progression, while these interactions compromise the activity of immune cells, leading to immune evasion and disease progression. Understanding these interactions can help in the development of improved treatments for multiple myeloma.